Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings

Executive Summary

Open-label extension Phase II data with RNAi candidate shows patients with transthyretin-mediated amyloidosis polyneuropathy may be regaining sensation and possibly even regenerating nerves.

Advertisement

Related Content

How Will Novel Agents Impact The HIV Market?
APOLLO Success Clears Alnylam For Lift-Off
Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints
PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches
Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen In Studies
Alnylam, Medicines Company PCSK9 Drug Has Quarterly Dose Potential
Alnylam gets $700m Sanofi investment, buys Sirna from Merck
US FDA rejects Pfizer rare neurodegenerative disease drug

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098625

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel